LIVIVO - Search results -

Search results

Result 1 - 10 of total 45

Search options

Article: Development of a Rainbow Trout (

Pasquariello, Rolando / Pavlovic, Radmila / Chacon, Marcelo A / Camin, Federica / Verdile, Nicole / Løkka, Guro / Panseri, Sara / Faustini, Massimo / Tandler, Amos / Peggs, David / Kortner, Trond M / Bitan, Amir / Brevini, Tiziana A L / Gandolfi, Fulvio

Animals : an open access journal from MDPI

2023 Volume 13, Issue 14

Abstract: The ever-increasing number and variation of raw materials utilized to provide alternative feed formulations continues to allow for a more sustainable and flexible approach. Testing all these ... ...

Abstract	The ever-increasing number and variation of raw materials utilized to provide alternative feed formulations continues to allow for a more sustainable and flexible approach. Testing all these options
Language	English
Publishing date	2023-07-12
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2606558-7
ISSN	2076-2615
ISSN	2076-2615
DOI	10.3390/ani13142278
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry.

Bekadja, Mohamed-Amine / Boumendil, Ariane / Blaise, Didier / Chevallier, Patrice / Peggs, Karl S / Salles, Gilles / Giebel, Sebastian / Marks, Reinhard / Arcese, William / Milpied, Noel / Finel, Herve / Gorin, Norbert Claude

Cytotherapy

2021 Volume 23, Issue 6, Page(s) 483–487

Abstract: Background aims: Around 50 000 autologous stem cell transplantations are done each year worldwide using cryopreserved peripheral blood stem cells (PBSCs). Cryopreservation is time-consuming and expensive. Since 2007, several retrospective studies have ... ...

Abstract	Background aims: Around 50 000 autologous stem cell transplantations are done each year worldwide using cryopreserved peripheral blood stem cells (PBSCs). Cryopreservation is time-consuming and expensive. Since 2007, several retrospective studies have shown that PBSCs can be stored at 4°C for 2-3 days, allowing autologous stem cell transplantation in patients with multiple myeloma receiving high-dose melphalan. Data with non-cryopreserved PBSCs in patients autografted for lymphoma following longer pre-conditioning regimens are limited. In addition, no controlled comparison has been able to detect unforeseen differences. Methods: The authors compared outcomes of 94 consecutive adult patients with lymphoma (66 with Hodgkin lymphoma) autografted in our department in Oran (Algeria) using PBSCs stored at 4°C, from 2009 to 2018, with patients receiving cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry. Patients autografted in Oran were matched with patients receiving cryopreserved PBSCs in the registry (four controls per patient in Oran). Results: Neutrophil engraftment was significantly faster with cryopreserved PBSCs (P = 0.003). By day 10, only 17% of patients receiving non-cryopreserved PBSCs engrafted versus 48% for cryopreserved PBSCs. Likewise, platelet recovery to 20 000/mm Conclusions: This analysis suggests that, in patients with lymphoma receiving pre-transplant regimens such as carmustine, etoposide, cytarabine and melphalan, PBSCs stored at 4°C for up to 6 days can be used safely in centers with no cryopreservation facility. However, the kinetics of hematopoietic recovery showed a significant, albeit small, delay in engraftment for both neutrophils and platelets, which favors the use of cryopreservation if available.
MeSH term(s)	Autografts ; Bone Marrow ; Cryopreservation ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma/therapy ; Matched-Pair Analysis ; Neoplasm Recurrence, Local ; Peripheral Blood Stem Cells ; Registries ; Retrospective Studies ; Transplantation, Autologous
Language	English
Publishing date	2021-03-04
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2039821-9
ISSN	1477-2566 ; 1465-3249
ISSN (online)	1477-2566
ISSN	1465-3249
DOI	10.1016/j.jcyt.2020.12.016
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5601: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Current Practice in Vitamin D Management in Allogeneic Hematopoietic Stem Cell Transplantation: A Survey by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.

Ros-Soto, J / Snowden, J A / Salooja, N / Gilleece, M / Parker, A / Greenfield, D M / Anthias, C / Alfred, A / Harrington, A / Peczynski, C / Peggs, K / Madrigal, A / Basak, G W / Schoemans, H

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

2019 Volume 25, Issue 10, Page(s) 2079–2085

Abstract: Beyond its impact on bone health, numerous studies have investigated the immune-regulatory properties of vitamin D and shown how its deficiency can affect outcomes in allogeneic hematopoietic stem cell transplantation (HSCT), particularly in acute or ... ...

Abstract	Beyond its impact on bone health, numerous studies have investigated the immune-regulatory properties of vitamin D and shown how its deficiency can affect outcomes in allogeneic hematopoietic stem cell transplantation (HSCT), particularly in acute or chronic graft-versus-host disease. This survey, carried out by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation (EBMT), describes the current clinical practice discrepancies across the EBMT HSCT programs. We therefore recommend the development of evidence-based guidelines to standardize evaluation criteria and to harmonize the management of vitamin D deficiency in patients undergoing allogeneic HSCT.
MeSH term(s)	Europe ; Female ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Male ; Surveys and Questionnaires ; Transplantation Conditioning/adverse effects ; Transplantation, Homologous/adverse effects ; Transplantation, Homologous/methods ; Vitamin D/pharmacology ; Vitamin D/therapeutic use ; Vitamin D Deficiency/therapy
Chemical Substances	Vitamin D (1406-16-2)
Language	English
Publishing date	2019-06-21
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1474865-4
ISSN	1523-6536 ; 1083-8791
ISSN (online)	1523-6536
ISSN	1083-8791
DOI	10.1016/j.bbmt.2019.06.015
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 462: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: CBETA: First Multipass Superconducting Linear Accelerator with Energy Recovery.

Bartnik, A / Banerjee, N / Burke, D / Crittenden, J / Deitrick, K / Dobbins, J / Gulliford, C / Hoffstaetter, G H / Li, Y / Lou, W / Quigley, P / Sagan, D / Smolenski, K / Berg, J S / Brooks, S / Hulsart, R / Mahler, G / Meot, F / Michnoff, R /

Peggs, S / Roser, T / Trbojevic, D / Tsoupas, N / Miyajima, T

Physical review letters

2020 Volume 125, Issue 4, Page(s) 44803

Abstract: Energy recovery has been achieved in a multipass linear accelerator, demonstrating a technology for more compact particle accelerators operating at higher currents and reduced energy consumption. Energy delivered to the beam during the first four passes ... ...

Abstract	Energy recovery has been achieved in a multipass linear accelerator, demonstrating a technology for more compact particle accelerators operating at higher currents and reduced energy consumption. Energy delivered to the beam during the first four passes through the accelerating structure was recovered during four subsequent decelerating passes. High-energy efficiency was achieved by the use of superconducting accelerating cavities and permanent magnets. The fixed-field alternating-gradient optical system used for the return loop successfully transported electron bunches of 42, 78, 114, and 150 MeV in a common vacuum chamber. This new kind of accelerator, an eight-pass energy recovery linac, has the potential to accelerate much higher current than existing linear accelerators while maintaining small beam dimensions and consuming much less energy per electron.
Language	English
Publishing date	2020-08-14
Publishing country	United States
Document type	Journal Article
ZDB-ID	208853-8
ISSN	1079-7114 ; 0031-9007
ISSN (online)	1079-7114
ISSN	0031-9007
DOI	10.1103/PhysRevLett.125.044803
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Bonn / Germany

Z 4' 58/153: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article: A review of recent work in sub-nanometre displacement measurement using optical and X-ray interferometry.

Peggs, G N / Yacoot, A

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences

2002 Volume 360, Issue 1794, Page(s) 953–968

Abstract: This paper reviews recent work in the field of displacement measurement using optical and X-ray interferometry at the sub-nanometre level of accuracy. The major sources of uncertainty in optical interferometry are discussed and a selection of recent ... ...

Abstract	This paper reviews recent work in the field of displacement measurement using optical and X-ray interferometry at the sub-nanometre level of accuracy. The major sources of uncertainty in optical interferometry are discussed and a selection of recent designs of ultra-precise, optical-interferometer-based, displacement measuring transducers presented. The use of X-ray interferometry and its combination with optical interferometry is discussed.
MeSH term(s)	Interferometry/instrumentation ; Interferometry/methods ; Microscopy, Interference/instrumentation ; Microscopy, Interference/methods ; Motion ; Nanotechnology/instrumentation ; Nanotechnology/methods ; X-Ray Diffraction/instrumentation ; X-Ray Diffraction/methods
Language	English
Publishing date	2002-05-15
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	208381-4
ISSN	1471-2962 ; 1364-503X ; 0080-4614 ; 0264-3820 ; 0264-3952
ISSN (online)	1471-2962
ISSN	1364-503X ; 0080-4614 ; 0264-3820 ; 0264-3952
DOI	10.1098/rsta.2001.0976
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Bonn / Germany

Z 4' 46/25: Show issues
Z PHI 2: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The evolution of non-small cell lung cancer metastases in TRACERx.

Al Bakir, Maise / Huebner, Ariana / Martínez-Ruiz, Carlos / Grigoriadis, Kristiana / Watkins, Thomas B K / Pich, Oriol / Moore, David A / Veeriah, Selvaraju / Ward, Sophia / Laycock, Joanne / Johnson, Diana / Rowan, Andrew / Razaq, Maryam / Akther, Mita / Naceur-Lombardelli, Cristina / Prymas, Paulina / Toncheva, Antonia / Hessey, Sonya / Dietzen, Michelle /

Colliver, Emma / Frankell, Alexander M / Bunkum, Abigail / Lim, Emilia L / Karasaki, Takahiro / Abbosh, Christopher / Hiley, Crispin T / Hill, Mark S / Cook, Daniel E / Wilson, Gareth A / Salgado, Roberto / Nye, Emma / Stone, Richard Kevin / Fennell, Dean A / Price, Gillian / Kerr, Keith M / Naidu, Babu / Middleton, Gary / Summers, Yvonne / Lindsay, Colin R / Blackhall, Fiona H / Cave, Judith / Blyth, Kevin G / Nair, Arjun / Ahmed, Asia / Taylor, Magali N / Procter, Alexander James / Falzon, Mary / Lawrence, David / Navani, Neal / Thakrar, Ricky M / Janes, Sam M / Papadatos-Pastos, Dionysis / Forster, Martin D / Lee, Siow Ming / Ahmad, Tanya / Quezada, Sergio A / Peggs, Karl S / Van Loo, Peter / Dive, Caroline / Hackshaw, Allan / Birkbak, Nicolai J / Zaccaria, Simone / Jamal-Hanjani, Mariam / McGranahan, Nicholas / Swanton, Charles

Nature

2023 Volume 616, Issue 7957, Page(s) 534–542

Abstract: Metastatic disease is responsible for the majority of cancer-related ... ...

Abstract	Metastatic disease is responsible for the majority of cancer-related deaths
MeSH term(s)	Humans ; Carcinoma, Non-Small-Cell Lung/pathology ; Clonal Evolution ; Clone Cells/pathology ; Cohort Studies ; Disease Progression ; Evolution, Molecular ; Lung Neoplasms/pathology ; Neoplasm Metastasis/diagnosis ; Neoplasm Metastasis/pathology ; Neoplasm Recurrence, Local
Language	English
Publishing date	2023-04-12
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	120714-3
ISSN	1476-4687 ; 0028-0836
ISSN (online)	1476-4687
ISSN	0028-0836
DOI	10.1038/s41586-023-05729-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 26: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 9: Show issues
Zs.MO 244: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting.

Blood advances

2021 Volume 5, Issue 21, Page(s) 4500–4503

MeSH term(s)	Acetates ; Cytomegalovirus ; Cytomegalovirus Infections/prevention & control ; Humans ; Quinazolines ; T-Lymphocytes
Chemical Substances	Acetates ; Quinazolines ; letermovir (1H09Y5WO1F)
Language	English
Publishing date	2021-10-04
Publishing country	United States
Document type	Journal Article ; Comment
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2021005637
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.

Roddie, Claire / Lekakis, Lazaros J / Marzolini, Maria A V / Ramakrishnan, Aravind / Zhang, Yiyun / Hu, Yanqing / Peddareddigari, Vijay G R / Khokhar, Nushmia / Chen, Robert / Basilico, Silvia / Raymond, Meera / Vargas, Frederick Arce / Duffy, Kevin / Brugger, Wolfram / O'Reilly, Maeve A / Wood, Leigh / Linch, David C / Peggs, Karl S / Bachier, Carlos /

Budde, Elizabeth Lihua / Lee Batlevi, Connie / Bartlett, Nancy / Irvine, David / Tholouli, Eleni / Osborne, Wendy / Ardeshna, Kirit M / Pule, Martin A

Blood

2022 Volume 141, Issue 20, Page(s) 2470–2482

Abstract: Relapse after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL) is commonly ascribed to antigen loss or CAR-T exhaustion. Multiantigen targeting and programmed cell death protein-1 blockade are rational ... ...

Abstract	Relapse after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL) is commonly ascribed to antigen loss or CAR-T exhaustion. Multiantigen targeting and programmed cell death protein-1 blockade are rational approaches to prevent relapse. Here, we test CD19/22 dual-targeting CAR-T (AUTO3) plus pembrolizumab in relapsed/refractory LBCL (NCT03289455). End points include toxicity (primary) and response rates (secondary). Fifty-two patients received AUTO3 and 48/52 received pembrolizumab. Median age was 59 years (range, 27-83), 46/52 had stage III/ IV disease and median follow-up was 21.6 months. AUTO3 was safe; grade 1-2 and grade 3 cytokine release syndrome affected 18/52 (34.6%) and 1/52 (1.9%) patients, neurotoxicity arose in 4 patients (2/4, grade 3-4), and hemophagocytic lymphohistiocytosis affected 2 patients. Outpatient administration was tested in 20 patients, saving a median of 14 hospital days per patient. Overall response rates were 66% (48.9%, complete response [CR]; 17%, partial response). Median duration of remission (DOR) for CR patients was not reached and for all responding patients was 8.3 months (95% confidence interval [CI]: 3.0-not evaluable). 54.4% (CI: 32.8-71.7) of CR patients and 42.6% of all responding patients were projected to remain progression-free at ≥12 months. AUTO3 ± pembrolizumab for relapsed/refractory LBCL was safe and delivered durable remissions in 54.4% of complete responders, associated with robust CAR-T expansion. Neither dual-targeting CAR-T nor pembrolizumab prevented relapse in a significant proportion of patients, and future developments include next-generation-AUTO3, engineered for superior expansion in vivo, and selection of CAR binders active at low antigen densities.
MeSH term(s)	Humans ; Middle Aged ; Receptors, Chimeric Antigen ; Neoplasm Recurrence, Local ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Immunotherapy, Adoptive ; T-Lymphocytes ; Antigens, CD19 ; Sialic Acid Binding Ig-like Lectin 2
Chemical Substances	Receptors, Chimeric Antigen ; Antigens, CD19 ; CD22 protein, human ; Sialic Acid Binding Ig-like Lectin 2
Language	English
Publishing date	2022-11-28
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood.2022018598
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.

Rule, Simon / Cook, Gordon / Russell, Nigel H / Hunter, Ann / Robinson, Stephen / Morley, Nick / Sureda, Anna / Patrick, Pip / Clifton-Hadley, Laura / Adedayo, Toyin / Kirkwood, Amy / Peggs, Karl S

British journal of haematology

2018 Volume 184, Issue 6, Page(s) 999–1005

Abstract: Mantle cell lymphoma (MCL) is an aggressive form of non-Hodgkin lymphoma that remains incurable for the majority of patients. Allogeneic stem cell transplantation (alloSCT) produces long-term disease-free remissions for around 30-40% patients, however it ...

Abstract	Mantle cell lymphoma (MCL) is an aggressive form of non-Hodgkin lymphoma that remains incurable for the majority of patients. Allogeneic stem cell transplantation (alloSCT) produces long-term disease-free remissions for around 30-40% patients, however it is reserved for the treatment of relapsed disease. This study examined the use of front line transplantation for young patients in an attempt to improve outcomes. Twenty-five patients received an alloSCT using BEAM [BCNU (carmustine), etoposide, cytarabine, melphalan)-Campath conditioning following permissive induction therapy from both related and unrelated donors. This was a multi-centre prospective trial. Twenty-four of 25 patients engrafted with no non-relapse mortality events by day 100. With a median follow-up of 60·5 months, there have been six deaths (3 from MCL). The progression-free survival (PFS) and overall survival were 68% and 80% at 2 years and 56% and 76% at 5 years. PFS was very similar for both sibling and unrelated transplants and there was no difference in PFS between patients with respect to remission status prior to transplantation. Nine (38%) patients experienced acute graft-versus-host disease (GVHD) and 14 (58%) experienced chronic GVHD, of which 8 were extensive. Front line alloSCT is feasible but should only be considered for patients at high risk of early progression following conventional therapy.
MeSH term(s)	Adult ; Aged ; Female ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Lymphoma, Mantle-Cell/pathology ; Lymphoma, Mantle-Cell/therapy ; Lymphoma, Non-Hodgkin/pathology ; Lymphoma, Non-Hodgkin/therapy ; Male ; Middle Aged ; Transplantation Conditioning/methods ; Transplantation, Homologous/methods
Language	English
Publishing date	2018-12-17
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80077-6
ISSN	1365-2141 ; 0007-1048
ISSN (online)	1365-2141
ISSN	0007-1048
DOI	10.1111/bjh.15723
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure.

Mohamedbhai, Sajir G / Edwards, Noha / Morris, Emma C / Mackinnon, Stephen / Thomson, Kirsty J / Peggs, Karl S

British journal of haematology

2012 Volume 156, Issue 4, Page(s) 516–522

Abstract: The clinical significance of mixed chimerism following allogeneic haematopoietic stem cell transplantation (HSCT) remains controversial. Its relevance and incidence are probably influenced by the conditioning regimen and incorporation of T-cell depletion. ...

Abstract	The clinical significance of mixed chimerism following allogeneic haematopoietic stem cell transplantation (HSCT) remains controversial. Its relevance and incidence are probably influenced by the conditioning regimen and incorporation of T-cell depletion. The presence of recipient chimerism levels >40-50% following T-cell replete reduced intensity transplantation correlates with a high risk of graft rejection, regardless of donor-lymphocyte infusions, but it is unclear whether this finding translates to T-cell depleted transplants. We conducted a retrospective single-institution analysis of patients receiving alemtuzumab-based HSCT. 27/152 (18%) evaluable cases had predominantly recipient T-cell chimerism at 3 months or beyond. By contrast, coincident chimerism in the granulocyte lineage was predominantly of donor origin (median 100%) in all but one patient. Donor lymphocyte infusion effectively converted predominantly recipient T-cell chimerism to ful donor chimerism in all evaluable cases including three cases with no detectable donor T cells. The only graft failure occurred in the patient with predominantly recipient myeloid chimerism in whom rejection occurred rapidly before donor lymphocytes could be administered. We conclude that predominant or complete recipient T-cell chimerism following alemtuzumab-based regimens does not have the same clinical implications as that following T-cell replete transplants and can be effectively converted with donor lymphocytes without the need for lympho-depleting agents or re-conditioning.
MeSH term(s)	Adolescent ; Adult ; Aged ; Alemtuzumab ; Antibodies, Monoclonal, Humanized/therapeutic use ; Female ; Graft Rejection ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Leukemia/drug therapy ; Leukemia/therapy ; Lymphocyte Depletion ; Lymphocyte Transfusion ; Lymphoma/drug therapy ; Lymphoma/therapy ; Male ; Middle Aged ; Retrospective Studies ; T-Lymphocytes/drug effects ; Transplantation Chimera ; Transplantation, Homologous ; Young Adult
Chemical Substances	Antibodies, Monoclonal, Humanized ; Alemtuzumab (3A189DH42V)
Language	English
Publishing date	2012-02
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80077-6
ISSN	1365-2141 ; 0007-1048
ISSN (online)	1365-2141
ISSN	0007-1048
DOI	10.1111/j.1365-2141.2011.08944.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito